HBMN HBM Healthcare Investments AG Ord
HBM Healthcare Investments AG specializes in fund of funds and direct investments in middle market and mature companies. The fund prefers to invest in start up, early stage, mid stage, mid venture, late venture, and late stage private companies, unlisted emerging companies, small cap public companies, buyouts, growth capital, and private investment in public equities (PIPES). Within fund of funds, it invests in venture capital funds. It also seeks to finance spin-offs of product lines or departments from larger corporations and the expansion or restructuring of established companies, seed stages, venture capital, expansion capital stages, spin-offs, and buyouts. The fund prefers to invest in the private and public companies in the healthcare sector with a focus on human medicine, drugs, pharma , biopharma, biotechnology, diagnostics, medical technology, and related industries. It seeks to make initial investments in companies whose primary products are in clinical development or the immediately preceding stage. The fund typically invests globally with a focus on Asia Pacific, Asia, North America, and Europe. In case of public companies, it focuses on those which originate from its private portfolio. The fund increases its investment in portfolio companies by participating in a follow-on financing or after the portfolio company's IPO. It may acquire majority participations in portfolio companies, usually takes a seat on the portfolio company's Board of Directors, and largely makes equity investments but may also invest through other instruments including convertible bonds, debt securities, structured products, and derivatives. The fund exits its portfolio companies through trade sale or IPO.…
Industry Peers
Capital MarketsKey Statistics
About HBM Healthcare Investments AG Ord (SWX: HBMN)
›
HBM Healthcare Investments AG Ord (SWX: HBMN) is listed on the SIX Swiss Exchange, where its shares trade in CHF. It belongs to the Capital Markets industry, part of the Financial Services sector.
The shares were at 213.00 CHF on 20 November 2026, up 6.6% over 52 weeks. Its 52-week range is 198.60 CHF to 258.00 CHF: the price is 17.4% below the high and 7.3% above the low.
At a market capitalisation of 1.37B CHF, it trades at 4.0 times trailing earnings and 13.3 times forward earnings. The median trailing P/E of its 20 largest Capital Markets peers is 15.0, a discount of 73% for HBMN. It pays a dividend yielding 4.12% (it pays out 17% of its earnings), against a median of 2.01% among the dividend payers in that peer group.
HBM Healthcare Investments AG Ord reports return on equity of 14.7% and an operating margin of 99.3%.
Its debt exceeds its cash by 170.58M CHF, a debt-to-equity ratio of 0.05. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. One analyst covers the stock; their mean price target of 280.00 CHF is 31.5% above the current price. The next earnings report is expected on 22 January 2027.